TNGX: Vopimetostat delivers breakthrough efficacy in cancer, with pivotal data and regulatory updates ahead
Vopimetostat, a PRMT5 inhibitor, has shown unprecedented response rates in pancreatic cancer and is advancing toward regulatory approval, with a strong focus on combination therapies and expansion into lung cancer and glioblastoma. Mature data updates and regulatory strategy details are expected by…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.